Publications
Detailed Information
Comparative Efficacy of Two PRRSV and PCV2 Vaccines : 두 가지 PRRSV와 PCV2 백신의 효능 비교 평가
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | 채찬희 | - |
dc.contributor.author | 강희석 | - |
dc.date.accessioned | 2017-10-27T17:00:36Z | - |
dc.date.available | 2017-10-27T17:00:36Z | - |
dc.date.issued | 2017-08 | - |
dc.identifier.other | 000000145099 | - |
dc.identifier.uri | https://hdl.handle.net/10371/137011 | - |
dc.description | 학위논문 (박사)-- 서울대학교 대학원 수의과대학 수의학과, 2017. 8. 채찬희. | - |
dc.description.abstract | Porcine reproductive and respiratory syndrome (PRRS) induced by PRRS virus (PRRSV) has led to the most devastating economic losses in the global swine industry because PRRSV causes reproductive failure in breeding herds and respiratory disorder in growing/finishing pigs. Vaccination has become the most common strategic method for the prevention and control of PPRSV infection. Since simultaneous immunization is an efficient tool for controlling the co-challenge of PCV2 and PRRSV infection, the objective of the first study was to compare clinical, virological, immunological, and pathological indicators in pigs each treated simultaneously with both PRRSV and porcine circovirus type 2 (PCV2) vaccines from one of two commercial products and then later exposed to field strains of both viruses. Pigs in one group vaccinated with Fostera PCV and Fostera PRRS simultaneously and pigs in another group vaccinated with Ingelvac CircoFLEX and Ingelvac PRRS MLV simultaneously on study day -28 (21 days of age) were exposed to both viruses at study day 0 (49 days of age). No significant differences concerning transmission were seen between the two immunized groups in clinical, virological (except PCV2 viremia on day 14), immunological, or pathological examinations. Under these study conditions, there was no difference in protection whether PCV2 and PRRSV vaccines were administered simultaneously or not. The objective of the second study was to compare the efficacy of two modified live virus (MLV) PRRSV vaccines under field conditions. The clinical trial at the site was performed on a 1,000-sow herd with two-site generation: farrowing nursery and growing/finishing system. The farm had had difficult times because of losing animals due to respiratory disease brought on by PRRSV-2 in postweaning and late growing pigs at the same time of study. Via intramuscular injections, pigs in Group 1 were administered with 2.0 mL of the Fostera PRRS vaccine (Zoetis, Lot No. A405013B), pigs in Group 2 were administered with 2.0 mL of the Ingelvac PRRS MLV (Boehringer Ingelheim Vetmedica Inc., Lot No. 245-659A) and pigs in Group 3 were administered with 2.0 mL of phosphate buffered saline (0.01M, pH 7.4). This study indicated that pigs immunized with MLV vaccines Fostera PRRS (Zoetis, Florham New Jersey) and Ingelvac PRRS MLV (Boehringer Ingelheim Vetmedica Inc., St Joseph Missouri) showed better growth performance and less lung lesions than unvaccinated controls under wild conditions. Moreover, no significant differences were detected between the MLV PRRSV vaccines in this study based on clinical (average daily weight gain), immunologic (antibodies), virologic (PCR testing), and pathologic (lesions and viral antigen) measurements. | - |
dc.description.tableofcontents | GENERAL INTRODUCTION 1
LITERATURE REVIEW 7 1. PRRS 7 2. PRRSV 8 3. Clinical Signs of PRRS 9 4. Infectious Activity of PRRSV 9 4.1 Breeding Herd 10 4.2 Piglets 11 4.3 Weaned and Growing Pigs 11 5. PRRSV Immunity 11 6. PRRSV MLV (Attenuated) Vaccine 15 6.1 Protective Efficacy 16 6.2 Safety 18 6.3 Commercial Product 20 6.3.1 Ingelvac PRRS MLV 20 6.3.2 Fostera PRRS 21 7. PMWS 22 8. PCV2 25 9. Clinical Signs of PCV2 27 10. Infectious Activity of PCV2 30 10.1 Sows 31 10.2 Fetuses 32 11. PCV2 Immunity 32 12. PCV2 Vaccine 38 12.1 Protective Efficacy 41 12.2 Safety 42 12.3 Commercial Product 44 12.3.1 Ingelvac CircoFLEX 44 12.3.2 Fostera PCV 45 13. Interaction between PCV2 and PRRSV 46 14. Correlation between efficacy and genetic similarity in the vaccine viruses 36 REFERENCES 51 PART 1. Comparative efficacy of concurrent administration of a porcine circovirus type 2 (PCV2) vaccine plus a porcine reproductive and respiratory syndrome virus (PRRSV) vaccine from two commercial sources in pigs challenged with both viruses 86 Abstract 86 1. Introduction 87 2. Materials and Methods 89 3. Results 96 4. Discussion 114 References 118 PART 2. Comparison of growth performance under field conditions in growing pigs each vaccinated with one of two commercial modified-live porcine reproductive and respiratory syndrome vaccines 125 Abstract 125 1. Introduction 127 2. Materials and Methods 127 3. Results 133 4. Discussion 139 References 142 국문 논문 초록 146 | - |
dc.format | application/pdf | - |
dc.format.extent | 1711917 bytes | - |
dc.format.medium | application/pdf | - |
dc.language.iso | en | - |
dc.publisher | 서울대학교 대학원 | - |
dc.subject | Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) | - |
dc.subject | Porcine Circovirus Type 2 (PCV2) | - |
dc.subject | Vaccine | - |
dc.subject | Fostera | - |
dc.subject | Ingelvac | - |
dc.subject.ddc | 636.089 | - |
dc.title | Comparative Efficacy of Two PRRSV and PCV2 Vaccines | - |
dc.title.alternative | 두 가지 PRRSV와 PCV2 백신의 효능 비교 평가 | - |
dc.type | Thesis | - |
dc.contributor.AlternativeAuthor | Hei Suk Kang | - |
dc.description.degree | Doctor | - |
dc.contributor.affiliation | 수의과대학 수의학과 | - |
dc.date.awarded | 2017-08 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.